China Resources Sanjiu 2025 Annual Report Analysis: Revenue up 14.43%, Financial Expenses Surge by 244.67%

Operating Revenue: Steady Growth Driven by Dual Engines

In 2025, China Resources Sanjiu achieved an operating revenue of 31.603 billion yuan, a year-on-year increase of 14.43%. In terms of business segments, the prescription drug sector performed exceptionally well, generating revenue of 12.094 billion yuan, a substantial year-on-year growth of 101.38%, becoming the core driver of revenue growth, mainly due to the integration and synergy effects released after acquiring Tasly. The self-medication (CHC) business generated revenue of 15.111 billion yuan, a year-on-year decline of 14.67%, primarily impacted by the decrease in incidence rates of influenza and other respiratory diseases, putting pressure on the sales of core categories. By region, the northern region’s revenue was 6.206 billion yuan, a significant year-on-year increase of 48.68%, while the revenue in East China reached 8.671 billion yuan, up 16.90% year-on-year, indicating strong growth momentum in the regional markets.

Net Profit: Slowing Growth, Increased Contribution from Non-Recurring Gains

In 2025, the company reported a net profit attributable to shareholders of the listed company of 3.421 billion yuan, a year-on-year increase of 1.58%, with growth significantly slowing compared to revenue. The net profit after deducting non-recurring gains was 3.134 billion yuan, only a 0.52% increase year-on-year, indicating weak growth in core business profitability. The contribution of non-recurring gains to net profit increased, totaling 287 million yuan for the year, up 37 million yuan year-on-year, mainly from government subsidies and gains from changes in the fair value of financial assets.

Earnings Per Share: Slight Growth in Line with Net Profit

In 2025, the company’s basic earnings per share were 2.06 yuan/share, a year-on-year increase of 1.98%; the earnings per share after deducting non-recurring items were 1.88 yuan/share, a year-on-year increase of 0.54%. The growth rate of earnings per share is largely in line with that of net profit, reflecting that the company’s capital expansion matches its profit growth.

Expenses: Overall Significant Growth, Driven by Integration and R&D Investment

In 2025, the company’s total period expenses amounted to 12.290 billion yuan, a year-on-year increase of 25.07%, with the growth rate of expenses significantly higher than that of revenue, putting pressure on profitability.

Sales Expenses: Increased Investment in Channels and Brands

Sales expenses reached 9.089 billion yuan, a year-on-year increase of 25.88%. The main reasons include: first, following the integration of the prescription drug sector, market investments such as academic promotions have increased; second, in response to market competition, the CHC business has continuously strengthened brand marketing and channel development, especially increasing investments in online channels.

Management Expenses: Rising Integration and Governance Costs

Management expenses amounted to 1.898 billion yuan, a year-on-year increase of 14.48%. This was mainly due to the management synergy costs and organizational restructuring costs incurred during the integration after acquiring Tasly, along with increased investments in digital transformation and compliance governance.

Financial Expenses: Turning from Negative to Positive, Significant Increase in Interest Expenses

Financial expenses were 0.035 billion yuan, a significant year-on-year increase of 244.67%, turning from a net income last year to net expenditure. The main reason is that the company increased its borrowing scale for the acquisition of Tasly, resulting in a substantial year-on-year increase in interest expenses, while interest income decreased.

R&D Expenses: Continued Increased Investment in Innovation

R&D expenses were 1.268 billion yuan, a year-on-year increase of 58.16%. The company has continued to increase its R&D investment in innovative drugs, improved new drugs, and classic formulas, with total R&D investment reaching 1.734 billion yuan for the year, a year-on-year increase of 81.90%, and the proportion of R&D investment to operating revenue rising to 5.49%. Among them, capitalized R&D investment was 0.469 billion yuan, a year-on-year increase of 210.33%, and the capitalization rate rose to 27.07%, accelerating the transformation of innovative achievements.

R&D Personnel Situation: Doubling in Size, Optimized Structure

In 2025, the number of R&D personnel in the company reached 2,241, a substantial year-on-year increase of 155.82%, mainly due to the inclusion of Tasly’s R&D team following the acquisition. From the perspective of educational background, there were 927 R&D personnel with a master’s degree or higher, accounting for 41.37%; from the age structure, there were 1,023 R&D personnel aged 30-40, accounting for 45.65%, becoming the core force in R&D, with both the scale and quality of the R&D team significantly improved.

Cash Flow: Steady Operating Cash Flow, Significant Net Outflow in Investment Cash Flow

Operating Cash Flow: High Quality, Resilience Highlighted

The net cash flow generated from operating activities was 5.513 billion yuan, a year-on-year increase of 25.23%, with growth exceeding that of net profit. Cash received from the sale of goods and provision of services reached 33.939 billion yuan, a year-on-year increase of 21.44%, and the cash conversion rate of revenue remained at a high level, reflecting the company’s strong cash flow generation capability from its main business and excellent profit quality.

Investment Cash Flow: Significant Increase in Acquisition and Investment Expenditures

The net cash flow generated from investing activities was -7.410 billion yuan, representing a significant net outflow increase of 555.53% year-on-year. The main reason was the company’s completion of the acquisition of Tasly, with total acquisition payments and related investment expenditures amounting to 20.266 billion yuan, while cash received from investment recoveries was 12.429 billion yuan, resulting in an overall large net outflow in investment activities.

Financing Cash Flow: Increased Financing Efforts

The net cash flow generated from financing activities was 1.564 billion yuan, turning from net outflow last year to net inflow year-on-year. This was mainly due to the company increasing its borrowing scale to meet acquisition and business development needs, obtaining cash from borrowings of 6.544 billion yuan, while repaying debt expenditures of 3.086 billion yuan, providing funding support for the company’s expansion through financing activities.

Potential Risks: Multiple Challenges Testing Integration and Adaptability

Market and Policy Risks

The normalization of drug procurement, ongoing price governance, and policies such as the post-marketing evaluation of traditional Chinese medicine injections may impact the revenue and profitability of some of the company’s products; regulations in the pharmaceutical industry may impose constraints on market promotion activities, which may temporarily affect the sales rhythm of products.

R&D Innovation Risks

The drug development cycle is long, requires significant investment, and has a high failure rate. With increased R&D investment, the risk of failure in developing new products has risen, and changes in policies, regulations, and market competition dynamics may also affect the commercialization prospects of R&D projects.

Merger and Integration Risks

The integration following the acquisition of Tasly is still ongoing, and there may be risks related to cultural integration and business synergies not meeting expectations. Changes in the market and policy environment may also lead to deviations in the market potential and profitability forecasts for the merger project.

Raw Material Price Volatility Risks

The prices of traditional Chinese medicinal materials are influenced by various factors such as natural conditions, supply and demand, and policy regulation, and price fluctuations may increase the company’s production costs, impacting profitability stability.

Executive Compensation: Core Management Compensation Linked to Performance

Chairman’s Compensation

The chairman, Qiu Huaiwei, received a total pre-tax compensation of 3.1464 million yuan from the company during the reporting period, with the compensation level linked to the company’s overall performance and the effectiveness of strategic advancement, reflecting recognition of his leadership in achieving the “14th Five-Year” strategic goals and promoting merger integration.

General Manager’s Compensation

The general manager, Wu Wendo, had a total pre-tax compensation of 1.6736 million yuan during the reporting period, closely related to the company’s operating performance and the progress of business integration, reflecting the company’s incentives and constraints on the core operating management team.

Vice President’s Compensation

Vice presidents Zhou Hui, Mai Yi, and Wang Liang received total pre-tax compensations of 2.5232 million yuan, 2.2962 million yuan, and 2.2717 million yuan respectively during the reporting period, with compensation levels related to the performance of their respective business segments and the execution of strategies, incentivizing management to focus on business development and collaborative integration.

Chief Financial Officer’s Compensation

The chief financial officer, Xing Jian, received a total pre-tax compensation of 787,000 yuan during the reporting period, with his compensation related to the effectiveness of the company’s financial management, capital operations, merger financing, etc., ensuring the stable operation of the company’s financial system.

Click to view the original announcement>>

Disclaimer: The market has risks; investment requires caution. This article is automatically published by an AI model based on third-party databases and does not represent the views of Sina Finance. Any information appearing in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for any discrepancies. For inquiries, please contact biz@staff.sina.com.cn.

A wealth of information and precise interpretations can be found in the Sina Finance APP

Editor: Xiaolang Express Report